Thank you for taking the time to learn about Bexa. We’re working hard to continuously advance the sophistication of Bexa and to establish its role in the early detection of breast cancer through continued use and traditional clinical validation studies. Both are delivering great results.
The Bexa Team, Advisors, and Board of Directors are squarely focused on the lack of both participation in and access to early detection options, a quiet but very real tragedy. Globally 90% of women have no technology-assisted early detection option: that’s 1.3 billion women with little chance to beat the most common women’s cancer. In the U.S., based upon insurance claims data (a very good measure of reality) fewer than 40% of women have an annual exam beginning at age 40 - mammogram, ultrasound or other - even though “every year beginning at age 40,” remains the most effective regimen and is endorsed by leaders in every clinical specialty that deals with breast cancer. During Covid, very few women are getting any form of early detection, making a bad problem much worse. Within these broad populations are women who are especially left behind. Women in rural and low-income settings frequently set aside self-protection because of a lack of resources, access or the income insecurity caused by time-consuming processes. African American women are commonly being diagnosed 3 to 4 years earlier and should start screening at age 35. No woman should be so dramatically left behind. Early detection is the critical factor in determining the suffering and death, and cost produced by invasive breast cancers. There’s no surgery, no drug, no therapy that makes up for the impact of a breast cancer being diagnosed late that may have been able to be diagnosed early.
Late-stage breast cancers aren’t a “women’s problem”; they are every society’s problem because the impact of late-stage cancers is far broader than just medical outcomes and cancer treatment costs.Families are destabilized, income lost, school performance is affected…as a survivor told me early in our journey, “everything is affected, and a lot is lost.”
We’re working hard to be a team that’s listening and acting. We ‘heard’ that there’s a need for a technology that’s painless and easily accessed: Bexa. We ‘hear’ from women that follow-up appointments can be a challenge; now, we have resources that help women secure timely follow-up. We ‘hear’ that speaking directly with a doctor about early detection questions is valuable; we now make those discussions immediately available. In all of this, we thank you for your interest in Bexa. We appreciate any support that advances the mission of the Bexa team: No woman left behind.
Joe Peterson, MD Chairman & CEO